[Treatment of supratentorial glioma with intracarotid cisplatin and intravenous carmustine].
We report the results of intracarotid (IC) cisplatinum and intravenous carmustine (BCNU) in 26 patients with supratentorial malignant glioma and recurrent low grade glioma. A response rate of 53.84% (95% confidence interval 33.3%-73.4%) was found. The median survival for the whole group was 11 months (range 3-70), with 35% of patients surviving for 2 years. At the present time, 5 patients are still alive, with a median follow up of 68 months (range 56-70). Neurological toxicity has been low and transient, being attributable to the technical degree of care in catheter positioning, cisplatin dosage and the technique of drug administration into the carotid artery.
Rebollo
J
J
Departamentos de Oncología Médica, Clínica Universitaria de Navarra, Pamplona.
Martín-Algarra
S
S
Bilbao
I
I
Zubieta
J L
JL
Calvo
F A
FA
de Castro
P
P
Pastor
M A
MA
Viteri
C
C
Martínez Lage
J M
JM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D002330:Carmustine / Q000008:administration & dosage; D002339:Carotid Arteries; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D006801:Humans; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012074:Remission Induction; D013030:Spain / Q000453:epidemiology; D015996:Survival Rate
D002945:Cisplatin; D002330:Carmustine
Tratamiento del glioma supratentorial con cisplatino intracarotídeo y carmustina intravenosa.